Clinical Trials | December 17, 2024
Merck to discontinue KeyVibe and Keyform clinical trials
Merck has also decided to end the favezelimab clinical development program
Merck has also decided to end the favezelimab clinical development program
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International
A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%
Harnessing advanced data analysis for early detection, prevention and better outcomes
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Final decision from the European Commission is anticipated within the coming months
Subscribe To Our Newsletter & Stay Updated
